957 related articles for article (PubMed ID: 17128426)
1. Assessment of futility in clinical trials.
Snapinn S; Chen MG; Jiang Q; Koutsoukos T
Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
[TBL] [Abstract][Full Text] [Related]
2. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
3. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
Whitehead J; Matsushita T
Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
[TBL] [Abstract][Full Text] [Related]
4. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
Tan M; Xiong X; Kutner MH
Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
[TBL] [Abstract][Full Text] [Related]
6. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
7. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
8. Frequentist evaluation of group sequential clinical trial designs.
Emerson SS; Kittelson JM; Gillen DL
Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
[TBL] [Abstract][Full Text] [Related]
9. Implementing type I & type II error spending for two-sided group sequential designs.
Rudser KD; Emerson SS
Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
[TBL] [Abstract][Full Text] [Related]
10. Alternative views on setting clinical trial futility criteria.
Gallo P; Mao L; Shih VH
J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
[TBL] [Abstract][Full Text] [Related]
11. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
Yi J; Fang L; Su Z
Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
[TBL] [Abstract][Full Text] [Related]
12. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
13. A review of methods for futility stopping based on conditional power.
Lachin JM
Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
[TBL] [Abstract][Full Text] [Related]
14. Sample size and the probability of a successful trial.
Chuang-Stein C
Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
[TBL] [Abstract][Full Text] [Related]
15. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
Polley MY; Cheung YK
Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
[TBL] [Abstract][Full Text] [Related]
16. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
17. Power and sample size when multiple endpoints are considered.
Senn S; Bretz F
Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
[TBL] [Abstract][Full Text] [Related]
18. Issues in the use of adaptive clinical trial designs.
Emerson SS
Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553
[TBL] [Abstract][Full Text] [Related]
19. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.
Hughes S; Cuffe RL; Lieftucht A; Garrett Nichols W
Pharm Stat; 2009; 8(1):25-37. PubMed ID: 18383194
[TBL] [Abstract][Full Text] [Related]
20. A comparison of two methods for adaptive interim analyses in clinical trials.
Wassmer G
Biometrics; 1998 Jun; 54(2):696-705. PubMed ID: 9629649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]